Plain-English translation of NCT07532174 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
During heart surgery, your heart and lungs temporarily stop working, which can trigger harmful chemicals to enter your bloodstream and damage your organs. This trial tests whether a device called Efferon LPS—which filters harmful substances from your blood during and right after surgery—can prevent this damage from happening. Researchers want to know if this treatment is safe and whether it truly reduces serious complications after surgery.
After heart surgery, about 30% of patients develop acute kidney injury or other organ problems, which can extend hospital stays and worsen recovery. This medication is being tested because early evidence suggests it may remove dangerous chemicals from the blood and protect organs from failing.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will undergo your planned heart surgery. Half of participants will receive standard heart surgery care alone, while the other half will have the Efferon LPS blood-cleaning device connected during and shortly after surgery to filter harmful substances from their blood. Your medical team will monitor you closely during and after surgery to watch for any side effects and to track whether the treatment helps prevent organ complications.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
Russia